Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | SLC5A7 | Q9GZV3 | 4/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.45 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.44 |
| ▸ | NEK3 | P51956 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12725011 | 0.92 | TBK1 (0.56) | TBK1JAK2SLC5A7STK17AMYLK4 | |
| SCHEMBL13498345 | 0.88 | SLC5A7 (0.47) | TBK1JAK2SLC5A7STK17AMYLK4 | |
| SCHEMBL1634925 | 0.87 | SLC5A7 (0.46) | TBK1JAK2SLC5A7STK17AMYLK4 | |
| SCHEMBL1633244 | 0.85 | PDE5A (0.43) | — | |
| SCHEMBL1633767 | 0.83 | HRH3 (0.53) | SLC5A7STK17AMYLK4NEK3LIMK1 | |
| SCHEMBL1864706 | 0.83 | BRAF (0.49) | TBK1JAK2STK17AMYLK4NEK3 | |
| SCHEMBL1634946 | 0.82 | STK17A (0.45) | TBK1JAK2SLC5A7STK17AMYLK4 | |
| SCHEMBL1632408 | 0.80 | JAK2 (0.56) | TBK1JAK2SLC5A7STK17AMYLK4 | |
| SCHEMBL12725013 | 0.75 | LRRK2 (0.46) | TBK1JAK2 | |
| SCHEMBL13498298 | 0.75 | HRH3 (0.49) | JAK2SLC5A7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | TBK1 539/4885JAK2 1352/4885SLC5A7 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.